TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11836279

Group type: EXPERIMENTAL
Intervention: GH administration alone
Number of subjects: 31

Group type: COMPARATOR
Intervention: RT + placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: RT + GH
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: GH administration
Number of subjects: 31
Study: 10549114

Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid (HA) injection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: NSAIDs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Steroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid (HA) therapy
Number of subjects: 0
Study: 7723158

Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy (maintaining hemoglobin values between 100 and 120 g/L)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Restrictive transfusion strategy (maintaining hemoglobin values between 70 and 90 g/L)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy
Number of subjects: 69

Group type: COMPARATOR
Intervention: Restrictive transfusion strategy
Number of subjects: 69
Study: 2023348

Group type: EXPERIMENTAL
Intervention: 3 MIU interferon alfa-2a
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: 9 MIU interferon alfa-2a
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study: 6119940

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg of diazepam
Number of subjects: 13

Group type: COMPARATOR
Intervention: 3 X 10(‐1) mg/kg of fentanyl
Number of subjects: 13
Study: 30716400

Group type: EXPERIMENTAL
Intervention: Intensive Disease Management Program (DMP)
Number of subjects: 412

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 412
Study: 29331473

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 131

Group type: COMPARATOR
Intervention: Itraconazole
Number of subjects: 131
Study: 26802643

Group type: EXPERIMENTAL
Intervention: SQ grass sublingual immunotherapy (SLIT) tablet
Number of subjects: 0
Study: 25089277

Group type: EXPERIMENTAL
Intervention: Test meal after exercise
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 12

Group type: COMPARATOR
Intervention: Rest after exercise
Number of subjects: 12
Study: 21652583

Group type: EXPERIMENTAL
Intervention: High-dose (HD) chemotherapy with PBSCs
Number of subjects: 87

Group type: COMPARATOR
Intervention: Standard dose (SD) chemotherapy
Number of subjects: 87
Study: 18971768

Group type: EXPERIMENTAL
Intervention: Hypnotic induction with analgesic suggestion
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Hypnotic induction without analgesic suggestion
Number of subjects: 26

Group type: COMPARATOR
Intervention: Education about EMG (EDU)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Merged hypnosis groups (hypnotic induction with and without analgesic suggestion)
Number of subjects: 26
Study: 17149527

Group type: EXPERIMENTAL
Intervention: Tailored brief advice on alcohol problems
Number of subjects: 2562
Study: 16598110

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 2116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2116
Study: 14641849

Group type: EXPERIMENTAL
Intervention: Intradomestic residual spraying of lambda‐cyhalothrin, E.C., 25 mg/m2
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Spatial fogging of fenitrothion around the houses at 30 g/ha
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Intradomestic residual spraying of lambda‐cyhalothrin three times a year, at a dose slightly greater than 25 mg/m2
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Wall bioassays
Number of subjects: 2
Study: 11200148

Group type: EXPERIMENTAL
Intervention: Oral fluoropyrimidines (UFT plus leucovorin, capecitabine, eniluracil plus oral 5‐FU)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Irinotecan plus 5‐FU/leucovorin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxaliplatin plus 5‐FU/leucovorin
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5‐FU plus leucovorin
Number of subjects: 0
Study: 8975963

Group type: EXPERIMENTAL
Intervention: Erythromycin lactobionate 7 mg per kg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Normal saline (controls)
Number of subjects: 22
Study: 1736348

Group type: EXPERIMENTAL
Intervention: Budesonide enema (2 mg/100 ml)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 6342163

Group type: EXPERIMENTAL
Intervention: Miconazole nitrate and hydrocortisone (Daktacort)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Neomycin (Kenacomb)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Gentamicin-containing steroid ointment
Number of subjects: 85
Study: 31358242

Group type: EXPERIMENTAL
Intervention: Pediatric brain tumor survivors
Number of subjects: 157
Study: 29679749

Group type: EXPERIMENTAL
Intervention: SC peginterferon beta-1a 125 mcg every two weeks
Number of subjects: 1594

Group type: COMPARATOR
Intervention: SC interferon beta-1a 44 mcg three times per week
Number of subjects: 1594
Study: 26937774

Group type: EXPERIMENTAL
Intervention: Energy drink (Red Bull, 500 ml)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (PLA, noncaffeinated, sugar-free)
Number of subjects: 18
Study: 24508070

Group type: EXPERIMENTAL
Intervention: Retropubic tension-free vaginal tape (TVT) procedure
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Transobturator tension-free vaginal tape (TVT-O) procedure
Number of subjects: 95
Study: 22993936

Group type: EXPERIMENTAL
Intervention: Cycloferon in the complex treatment
Number of subjects: 60
Study: 20932189

Group type: EXPERIMENTAL
Intervention: SP6 acupuncture for 5 minutes after obtaining needling sensation (de qi) during menstrual pain (n=32)
Number of subjects: 66

Group type: COMPARATOR
Intervention: GB39 acupuncture for 5 minutes during menstrual pain (n=34)
Number of subjects: 66
Study: 17765564

Group type: EXPERIMENTAL
Intervention: Diluted Sanofi Pasteur smallpox vaccine
Number of subjects: 102
Study: 16324343

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg every night (Group B)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg every night (Group C)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Basal treatment (Group A)
Number of subjects: 131
Study: 12196338

Group type: EXPERIMENTAL
Intervention: Phenylephrine (PE)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Isoproterenol (ISO)
Number of subjects: 20
Study: 10197569

Group type: EXPERIMENTAL
Intervention: Exclusive breast-feeding (EBF) to 6 months
Number of subjects: 119

Group type: COMPARATOR
Intervention: Solid foods (SF) twice daily from 4 to 6 months
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Both groups (EBF and SF)
Number of subjects: 119
Study: 7766749

Group type: EXPERIMENTAL
Intervention: Khat leaves (Catha edulis)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lettuce
Number of subjects: 12
Study: 1967667

Group type: EXPERIMENTAL
Intervention: Bromocriptine 2.5 mg twice a day
Number of subjects: 272

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study: 7024154

Group type: EXPERIMENTAL
Intervention: Gastroplasty a.m. Gomez
Number of subjects: 28

Group type: COMPARATOR
Intervention: Very-low-calorie diet (341 kcal, 1.43 MJ) based on a high-value protein powder
Number of subjects: 28
Study: 31786155

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Fecal microbial transplantation from responders
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Machine-learning algorithm integrating baseline microbial signatures
Number of subjects: 39
Study: 30343116

Group type: EXPERIMENTAL
Intervention: Ozanimod (intervention in a phase 2 placebo-controlled trial)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: UC-100 score
Number of subjects: 179
Study: 29040763

Group type: EXPERIMENTAL
Intervention: Oxytocin (OT)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study: 25808169

Group type: EXPERIMENTAL
Intervention: D-cycloserine (50 mg)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: D-cycloserine (50 mg) and Placebo (PBO)
Number of subjects: 47
Study: 22404704

Group type: EXPERIMENTAL
Intervention: Quetiapine (300 or 600 mg/day)
Number of subjects: 584

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 584
Study: 21720429

Group type: EXPERIMENTAL
Intervention: Orlistat 60 mg
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study: 19789295

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine
Number of subjects: 18174

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 18174
Study: 18289495

Group type: EXPERIMENTAL
Intervention: IPD (Prevention of Delirium Interventions)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional care (Control)
Number of subjects: 60
Study: 15204466

Group type: EXPERIMENTAL
Intervention: Training Young Old Group (TYOG)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Training Old Group (TOG)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control Young Old Group (CYOG)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control Old Group (COG)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Training (TYOG and TOG)
Number of subjects: 42
Study: 11256381

Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 460

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 460
Study: 9498448

Group type: EXPERIMENTAL
Intervention: Finlay Institute (Havana) vaccine
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: National Institute of Public Health (Oslo) vaccine
Number of subjects: 408
Study: 7849954

Group type: EXPERIMENTAL
Intervention: Perflubron emulsion (0.15 to 0.50 mL) administered by subcutaneous injection
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Application of massage to the injection site
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Perflubron emulsion
Number of subjects: 18
Study: 3240893

Group type: EXPERIMENTAL
Intervention: Medical treatment with Ditropan 5 mg t.i.d. for 6 weeks prior to surgery (n = 21)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Surgical treatment (n = 18) with no prior treatment for bladder instability
Number of subjects: 39

Group type: COMPARATOR
Intervention: Surgical treatment (n = 18)
Number of subjects: 39
Study: 30421018

Group type: EXPERIMENTAL
Intervention: Overestimation ratio (overR)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Two-layered susceptibility vessel sign (TL-SVS)
Number of subjects: 258
Study: 28473118

Group type: EXPERIMENTAL
Intervention: Continued thienopyridine plus aspirin therapy for an additional 18 months
Number of subjects: 11648
Study: 26040633

Group type: EXPERIMENTAL
Intervention: Engagement in a minimum of 60 min of volunteer activities per week for 6 months
Number of subjects: 400

Group type: COMPARATOR
Intervention: Maintain existing lifestyle or take on new activities as they see fit
Number of subjects: 400
Study: 23447359

Group type: EXPERIMENTAL
Intervention: Teriflunomide 14 mg
Number of subjects: 1088

Group type: EXPERIMENTAL
Intervention: Teriflunomide 7 mg
Number of subjects: 1088

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1088
Study: 21496347

Group type: EXPERIMENTAL
Intervention: Marker Method
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Line of Femur Method
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 31
Study: 18048857

Group type: EXPERIMENTAL
Intervention: Intramuscular injections of BoNT‐A (BOTOX 100 U total) and intraarticular injection of normal saline
Number of subjects: 29

Group type: COMPARATOR
Intervention: Intraarticular injection of TA (40 mg) and intramuscular injection of normal saline
Number of subjects: 29
Study: 16863563

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) herbal formula containing 11 herbs
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 12641502

Group type: EXPERIMENTAL
Intervention: Triple antibiotic therapy (metronidazole 300 mg, clarithromycin 250 mg, and amoxicillin 500 mg, given four times daily for 2 weeks)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 15545314

Group type: EXPERIMENTAL
Intervention: Flurbiprofen microparticle formulation (3.125 mg, 6.25 mg, 12.5 mg, 25 mg, or 50 mg)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Flurbiprofen microparticle formulation (12.5 mg and higher doses)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 9990623

Group type: EXPERIMENTAL
Intervention: Unipolar configuration
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Lead configuration
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Shock energy (0.1 to 15 J)
Number of subjects: 25
Study: 8595479

Group type: EXPERIMENTAL
Intervention: Physostigmine infusion
Number of subjects: 0
Study: 2314826

Group type: EXPERIMENTAL
Intervention: Very-high-dose cisplatin (40 mg/m2/day for 5 days)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard-high-dose cisplatin (either a single dose of 100 or 20 mg/m2/day for 5 days)
Number of subjects: 31
Study: 303498

Group type: EXPERIMENTAL
Intervention: 100 mg of minocycline twice a day
Number of subjects: 60

Group type: COMPARATOR
Intervention: 75 mg of minocycline twice a day
Number of subjects: 60
Study: 30760243

Group type: EXPERIMENTAL
Intervention: Multi-component implementation strategy including obtaining executive support, training in-school champions, provision of tools and resources, implementation prompts, reminders and feedback
Number of subjects: 62

Group type: COMPARATOR
Intervention: Usual practice
Number of subjects: 62
Study: 26718667

Group type: EXPERIMENTAL
Intervention: Enriched formula (ENR)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard formula (ST)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Both groups (ENR and ST)
Number of subjects: 110
Study: 26577642

Group type: EXPERIMENTAL
Intervention: Weiss Functional Impairment Rating Scale-Parent Report Form (WFIRS-P)
Number of subjects: 7
Study: 23404824

Group type: COMPARATOR
Intervention: Weight Watchers (WW)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Combined treatment (CT)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Behavioral weight loss (BWL)
Number of subjects: 141
Study: 22485058

Group type: EXPERIMENTAL
Intervention: Breathing Awareness Meditation (BAM)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Life Skills (LS) training
Number of subjects: 121

Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 121
Study: 19761936

Group type: EXPERIMENTAL
Intervention: Atenolol-based therapy
Number of subjects: 12759

Group type: COMPARATOR
Intervention: Amlodipine-based therapy
Number of subjects: 12759
Study: 18093505

Group type: EXPERIMENTAL
Intervention: Calendar reminder of medication taking
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group (normal treatment)
Number of subjects: 220
Study: 15456436

Group type: EXPERIMENTAL
Intervention: Ropivacaine (active pump)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Normal saline (placebo pump)
Number of subjects: 48
Study: 11448321

Group type: EXPERIMENTAL
Intervention: 0.03% AGN 192024 once daily
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 0.003% AGN 192024 once daily
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 0.01% AGN 192024 once daily
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 0.03% AGN 192024 twice daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: 0.5% timolol twice daily
Number of subjects: 100
Study: 10405567

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy with alteplase (r-TPA), aspirin, glyceryl trinitrate
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy without reperfusion
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (healthy persons)
Number of subjects: 50
Study: 8296887

Group type: EXPERIMENTAL
Intervention: Brief adaptive psychotherapy
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Short-term dynamic psychotherapy
Number of subjects: 81

Group type: COMPARATOR
Intervention: Waiting list for therapy
Number of subjects: 81
Study: 3173455

Group type: EXPERIMENTAL
Intervention: Diet (energy intake reduction)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Exercise (increased energy expenditure)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Diet and Exercise
Number of subjects: 42
Study: 31816875

Group type: EXPERIMENTAL
Intervention: Nordic Diet (ND)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control Diet (CD)
Number of subjects: 88
Study: 28522220

Group type: EXPERIMENTAL
Intervention: Early ACL reconstruction
Number of subjects: 119

Group type: COMPARATOR
Intervention: Delayed ACL reconstruction
Number of subjects: 119

Group type: COMPARATOR
Intervention: Rehabilitation alone
Number of subjects: 119
Study: 25869840

Group type: EXPERIMENTAL
Intervention: Microdosing of (14)C-hRESCAP at 53 μg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapeutic doses of hRESCAP (up to 5.3 mg)
Number of subjects: 0
Study: 24620701

Group type: EXPERIMENTAL
Intervention: GameCycle
Number of subjects: 19

Group type: COMPARATOR
Intervention: Saratoga Silver I arm ergometer
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Text message reminders to exercise
Number of subjects: 19

Group type: COMPARATOR
Intervention: No reminders to exercise
Number of subjects: 19
Study: 21880193

Group type: EXPERIMENTAL
Intervention: Salmeterol/Fluticasone Propionate (SAL/FP) 50/250 μg, administered 2 inhalations BID for 2 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Fluticasone Propionate (FP) 250 μg, administered 2 inhalations BID for 2 weeks
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Salmeterol/Fluticasone Propionate (SAL/FP) 50/250 μg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Fluticasone Propionate (FP) 250 μg
Number of subjects: 48
Study: 19474112

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 4895

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 4895
Study: 17223304

Group type: EXPERIMENTAL
Intervention: Laparoscopic total mesorectal excision (LTME)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Open total mesorectal excision (OTME)
Number of subjects: 228
Study: 15089806

Group type: EXPERIMENTAL
Intervention: Moxonidine 0.4 mg orally
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 11152037

Group type: COMPARATOR
Intervention: Fentanyl-nitrous oxide
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Halothane-nitrous oxide
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Isoflurane-nitrous oxide
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sevoflurane-nitrous oxide
Number of subjects: 40
Study: 9863079

Group type: EXPERIMENTAL
Intervention: Combined acupuncture-drug anesthesia (dolantin 25 mg and droperidol 2.5 mg administered intravenously, with acupuncture stimulation at Neiguan (P6) and Hegu (LI4) for 30 minutes).
Number of subjects: 50

Group type: COMPARATOR
Intervention: 5% procaine combined with drug anesthesia (control group).
Number of subjects: 50
Study: 7868672

Group type: EXPERIMENTAL
Intervention: Reduced glutathione therapy
Number of subjects: 0
Study: 3280220

Group type: EXPERIMENTAL
Intervention: Verapamil 80 mg t.i.d. for one week
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg t.i.d. for one week
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Diltiazem 80 mg t.i.d. for one week
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Diltiazem 120 mg t.i.d. for one week
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High dose of both drugs
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both doses of diltiazem
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 36
Study: 30649752

Group type: EXPERIMENTAL
Intervention: Tralokinumab every 2 weeks (Q2 W)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Tralokinumab every 4 weeks (Q4 W)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Tralokinumab
Number of subjects: 52
Study: 29354968

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at specific acupoints (Neixiyan, Dubi, Yanglingquan, Yinlingquan, Xuehai, Liangqiu, Zusanli) with a frequency of 2 Hz for 3 weeks, 11 sessions total.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Minimal acupuncture at points located 2 cm next to the specified acupoints, no current applied.
Number of subjects: 40
Study: 26670300

Group type: EXPERIMENTAL
Intervention: Care Coordination for Health Promotion and Activities in Parkinson's Disease (CHAPS) intervention
Number of subjects: 346
Study: 23485520

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low fat-high carbohydrate diet (LF/HCD)
Number of subjects: 12
Study: 21515206

Group type: EXPERIMENTAL
Intervention: Fish-oil-based lipid emulsion (10% Omegaven)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 28
Study: 17393021

Group type: EXPERIMENTAL
Intervention: Enoxaparin 4,000 IU once daily
Number of subjects: 55

Group type: COMPARATOR
Intervention: Tinzaparin 4,500 IU once daily
Number of subjects: 55
Study: 16330294

Group type: COMPARATOR
Intervention: Diflucan (reference; Pfizer Corporation)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Funzol (test; Bosnalijek d.d.)
Number of subjects: 24
Study: 12324912

Group type: EXPERIMENTAL
Intervention: Q(a) (reduction of 1,000 mL/min)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: %UF (increase of 4%)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: MAP (reduction of 30 mm Hg)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Percentage decrease in Q(a) (> or =20% versus <20%)
Number of subjects: 105
Study: 9807203

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy (tamoxifen) in postmenopausal patients
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Polychemotherapy (CMF) in reproductive group
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Hormonal therapy (tamoxifen) in reproductive group
Number of subjects: 360
Study: 7657415

Group type: COMPARATOR
Intervention: Caffeine 0 mg.kg body weight-1 (placebo)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Caffeine 5 mg.kg body weight-1
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Caffeine 9 mg.kg body weight-1
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Caffeine 13 mg.kg body weight-1
Number of subjects: 9